Splash Clinical and C2N Diagnostics have collaborated to enhance the recruitment process for clinical trials of Alzheimer’s disease across the US and worldwide.
This collaboration involves a clinical trial recruitment programme from Splash Clinical, which unites its recruitment infrastructure with C2N’s PrecivityAD2 blood tests.
Go deeper with GlobalData
The PrecivityAD2 is designed for individuals aged 55 and above who exhibit signs or symptoms of mild cognitive impairment or dementia.
These tests are crucial for healthcare researchers and providers in detecting the brain’s amyloid plaques, which are indicative of Alzheimer’s, and claim to assist in making informed decisions on medical management and treatment.
According to Splash Clinical, PrecivityAD2’s diagnostic performance is on par with amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarker analysis.
The integration of C2N’s Precivity biomarker platform with Splash’s infrastructure aims to prepare subjects for clinical trials by streamlining the complex pre-screening process.
This approach is expected to lead to the qualification of subjects for trials, ultimately reducing the time and costs for trial sponsors.
The collaboration also features a “specialised” subject concierge service that aids in facilitating the pre-screening process, coordinating PrecivityAD2 testing, and managing trial participation.
Splash’s goal with this integrated solution is to decrease recruitment expenses and timelines, as well as uphold quality standards, and allow access to a diverse and wider population of trial subjects, ensuring they meet the criteria prior to their site visits.
C2N CEO Dr Joel Braunstein said: “C2N assays have been used in over 150 Alzheimer’s disease and other research studies, and we’re confident even more clinical trials will benefit as a result of this new initiative that seeks to ease recruitment and accuracy for all involved.”
This current partnership builds upon Splash Clinical’s collaborations in the central nervous system (CNS) area.
In September 2024, C2N secured an investment of up to $7.025m from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator to support its Alzheimer’s disease testing platform.
